Vera Health Raises $28.5M Series A for Clinician Evidence Platform

Vera Health announced a $28.5 million Series A funding round on October 27. The clinical AI platform, which has raised $32 million to date, will use the capital to accelerate its global expansion and evidence infrastructure.

The round was led by Threshold Ventures with participation from Optum Ventures, Mantis VC, and SV Angel. Existing investors Y Combinator and Gradient also increased their backing. The company, co-founded by Maxime Allouch and Taieb Bennani, grew from six to 12 employees while scaling its user base to over 800,000 clinicians worldwide.

Clinician Adoption and Evidence Framework

Vera Health now serves more than 800,000 clinicians across 190 countries. Its user base has grown from a few thousand daily questions a year ago to hundreds of thousands per day. The platform is free for licensed clinicians and medical trainees globally.

To answer queries, Vera searches over 60 million scientific publications, clinical guidelines, consensus statements, and drug labels. It evaluates each piece of research based on a multi-factor framework developed with clinicians who write medical guidelines. The system assesses study design, evidence quality, cohort size, risk of bias, recency, and citation impact. It checks for retractions and analyzes methodology rather than relying on author descriptions.

The platform does not make clinical recommendations. Instead, it presents evidence and its strength for clinician judgment. It highlights research limitations, conflicting evidence, and local guidance through color-coding and source linking. Bennani explained the philosophy behind this approach: "Language models are built to sound certain; medicine rarely is."

This process is built on four core principles: honesty, traceability, transparency, and context. A feature called Vera Spaces allows health systems to integrate their own clinical protocols alongside national and international guidelines.

Global Impact and Local Adaptation

Vera's growth is particularly strong in several European markets. The platform serves approximately one in four physicians in Spain and Italy and one in seven in France. The company implements a local-first approach to account for differing clinical guidelines by country.

Growth accelerates when 10% of a country's doctors adopt the platform. The company plans further expansion in Europe, with its first European hire based in Berlin.

Competitive Positioning

Vera operates in a space with several established and emerging competitors. These include Elsevier's ClinicalKey, Wolters Kluwer's UpToDate, OpenEvidence, Doximity Ask, OpenAI, and Anthropic.

The company differentiates through its clinician-built evidence evaluation and partnerships. It works with medical societies, publishers, and health systems, including integrating the American College of Emergency Physicians' clinical policies. Vera monetizes through tailored, institution-integrated versions of the platform for hospitals.

The company views Europe's strict data and AI regulations as a trust-building advantage. Vera aims to reduce the estimated 17-year gap between medical research publication and widespread clinical practice. The funding will support the expansion of its clinical evidence infrastructure and international partnerships.